NOWDiagnostics Taps MedTech Veteran to Lead At-Home Testing Revolution

By Timothy Bell

SPRINGDALE, AR – May 28, 2026 – In a strategic move poised to accelerate its push into the mainstream consumer health market, NOWDiagnostics, Inc. today announced the appointment of Lisa A. Nibauer as its new Chief Executive Officer. The Arkansas-based leader in rapid diagnostics is betting on Nibauer’s formidable track record of commercializing medical technologies and revitalizing consumer brands to steer its next phase of growth.

Nibauer, a 25-year veteran of the healthcare industry, steps into the role as Robert Weigle, who has led the company since 2023, transitions to a key advisory position on the Board of Directors. The leadership change comes at a pivotal moment for the company, which has already established a significant retail footprint and is now looking to capitalize on a promising pipeline of at-home diagnostic tests.

"Lisa is the ideal leader to guide NOWDiagnostics through our next chapter of innovative growth and scaling," said Dr. Stephen S. Tang, Chairman of the Board, in a statement. "Her exceptional track record in transforming diagnostic businesses, launching groundbreaking products, and scaling commercial operations directly aligns with our strategic priorities."

A Catalyst for Commercialization

Nibauer’s appointment is a clear signal of the board's intent to aggressively scale the company's commercial operations. Her resume reads like a playbook for exactly the challenges NOWDiagnostics faces: navigating complex regulatory pathways, securing large-scale distribution, and turning innovative technology into household products.

Most recently, as President of Diagnostics at OraSure Technologies, Nibauer spearheaded a 500-person organization, securing over $630 million in government contracts and achieving then-record annual revenue. Her tenure there was marked by the successful launch of an over-the-counter COVID-19 rapid test, a feat that involved navigating the FDA's Emergency Use Authorization process three times in a single year and establishing broad distribution in major U.S. retail stores and online.

Her experience extends beyond the recent rapid-test boom. During an eight-year stint at medical technology giant BD, she managed billion-dollar global businesses and drove the launch of multiple new diagnostic products. Perhaps most telling is her deep expertise in consumer healthcare, honed at Schering-Plough. There, she engineered a dramatic turnaround of the iconic Dr. Scholl's® brand, transforming an 11% revenue decline into 11% growth. She is also credited with creating the breakthrough Custom Fit Orthotics in-store kiosk concept, demonstrating a unique ability to bridge medical technology with retail consumer experience.

"Lisa's unique combination of diagnostic test development, regulatory expertise, and retail distribution excellence is exactly what NOWDiagnostics needs," commented Jeremy Wilson, Chair of the Compensation Committee. "Her ability to deliver results quickly... will be invaluable as we execute against our aggressive milestones."

Redefining At-Home Diagnostics

NOWDiagnostics has already carved out a niche with its proprietary FirstToKnow® platform, which uses a simple finger-stick of blood to deliver results in minutes. This technology underpins its current flagship products: the first and only FDA-authorized over-the-counter Syphilis self-test and an FDA-cleared blood-based pregnancy test, which are already available in over 15,000 retail locations.

However, the company's future ambitions lie in its pipeline. Nibauer herself highlighted a key project: a "potential first-in-class molecular Strep Throat test intended for OTC use." This product could be a game-changer. While rapid antigen strep tests are common in clinics, they often have lower sensitivity than laboratory-based molecular tests, sometimes requiring a follow-up culture. An accurate, at-home molecular test would represent a significant leap forward in consumer diagnostics, offering lab-grade accuracy from the convenience of home and potentially reducing unnecessary antibiotic prescriptions.

"I'm thrilled to join NOWDiagnostics at such a pivotal moment," Nibauer stated. "I see a tremendous opportunity to optimize our current products, accelerate our FDA submissions, and unlock the full potential of our technology platform."

This vision positions the company not just as a participant but as a potential leader in what could be called 'At-Home Diagnostics 2.0'—a market moving beyond simple tests to more complex, highly accurate molecular diagnostics that empower consumers with immediate, actionable health information.

A Strategic Handover for Sustained Growth

The leadership transition appears to be a carefully orchestrated move designed for strategic evolution rather than a course correction. Outgoing CEO Robert Weigle is credited with laying the critical groundwork for this next phase. Under his three-year leadership, the company launched its first OTC product, built its substantial retail network with major pharmacy chains, and advanced the molecular diagnostic platform that Nibauer will now carry forward.

"On behalf of the Board, I want to express our deep gratitude to Rob Weigle for his outstanding leadership," said Michele Colucci, Chair of the Audit Committee. She noted that Weigle positioned the company for "tremendous growth" and will remain a valuable asset as a board member and advisor.

Weigle himself endorsed the transition. "Leading NOWDiagnostics has been one of the most rewarding experiences of my career," he said. "Lisa is an exceptional leader with exactly the right background to take the company to new heights. I look forward to supporting her and the team in my continued role on the Board."

With Weigle ensuring continuity and Nibauer bringing a powerful new arsenal of commercial and regulatory expertise, NOWDiagnostics is making a bold statement. As the healthcare landscape continues to shift towards decentralization and consumer empowerment, the company has positioned a proven leader at the helm, equipped to navigate the competitive market and turn its technological innovations into commercial success.